Biologic therapies in psoriasis: a new therapeutic approach.

Chronic plaque psoriasis is an immune-mediated, inflammatory skin disease with a heavy burden on quality of life of patients. The disease has a chronic relapsing course and may be life long. Comorbid disorders include psoriatic arthritis, obesity, dyslipidemia, hypertension and an increased rate of cardiovascular disease. Conventional systemic treatments include methotrexate, cyclosporine and acitretin, which are associated with end organ toxicity that precludes long term therapy. Biological drugs are designed to selectively interfere with the immune mechanisms that induce psoriasis. Efalizumab is effective for skin psoriasis but not psoriatic arthritis. Anti-TNF-alpha agents (etanercept, infliximab and adalimumab) are active on both psoriasis and psoriatic arthritis. Infliximab is the most effective and rapid agent, but its safety profile may be less favourable. Moreover, efficacy can reduce over time. Etanercept is moderately active but has a better safety profile, and can be discontinued and re-used without loss of efficacy. The long term safety of all these agents has not been established.

[1]  S. Chimenti,et al.  Safety and efficacy study on etanercept in patients with plaque psoriasis , 2005, The British journal of dermatology.

[2]  A. Gottlieb,et al.  Etanercept as monotherapy in patients with psoriasis. , 2003, The New England journal of medicine.

[3]  A. Gottlieb,et al.  Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. , 2004, Journal of the American Academy of Dermatology.

[4]  A. Finlay,et al.  Patient‐reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial , 2005, The British journal of dermatology.

[5]  Steven R. Cohen,et al.  Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. , 2006, Journal of the American Academy of Dermatology.

[6]  A. Menter,et al.  Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. , 2005, Archives of dermatology.

[7]  A. Gottlieb,et al.  Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. , 2005, Journal of the American Academy of Dermatology.

[8]  R. Steinman,et al.  Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[9]  N. Cox,et al.  British Association of Dermatologists , 2001 .

[10]  J. Koo,et al.  Update on the mechanisms and efficacy of biological therapies for psoriasis. , 2005, Journal of dermatological science.

[11]  A. Gottlieb,et al.  A randomized trial of etanercept as monotherapy for psoriasis. , 2003, Archives of dermatology.

[12]  L. Heinzerling,et al.  Generalised Pustular Psoriasis Induced by Cyclosporin A Withdrawal Responding to the Tumour Necrosis Factor Alpha Inhibitor Etanercept , 2002, Dermatology.

[13]  S. Feldman,et al.  Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double‐blind placebo‐controlled trial , 2005, The British journal of dermatology.

[14]  A. Gottlieb,et al.  Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. , 2004, Journal of the American Academy of Dermatology.

[15]  D. Gladman,et al.  Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[16]  J. Bos,et al.  Effects of etanercept on quality of life, fatigue, and depression in psoriasis , 2006, The Lancet.

[17]  K. Joyce,et al.  The successful use of etanercept in combination therapy for treatment of acrodermatitis continua of hallopeau. , 2005, Journal of drugs in dermatology : JDD.

[18]  A. Gottlieb,et al.  Psoriasis treatment: current and emerging directed therapies , 2005, Annals of the rheumatic diseases.

[19]  F. Nestle,et al.  Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial , 2005, The Lancet.

[20]  U. Chaudhari,et al.  Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial , 2001, The Lancet.

[21]  M. Wener,et al.  Effect of tumour necrosis factor α antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection , 2003, Annals of the rheumatic diseases.

[22]  A. Finlay,et al.  British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005 , 2005, The British journal of dermatology.

[23]  F. Kerdel,et al.  Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type , 2002, International journal of dermatology.

[24]  A. Nakanishi,et al.  A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction , 2005, The British journal of dermatology.

[25]  M. Lebwohl,et al.  A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. , 2003, The New England journal of medicine.

[26]  J. Grabbe,et al.  Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor‐α antibody (infliximab) , 2004, The British journal of dermatology.

[27]  R. Gniadecki,et al.  Infliximab (Remicade) for acute, severe pustular and erythrodermic psoriasis. , 2004, Acta dermato-venereologica.